Blood arsenic Measured by change in GM of blood arsenic concentrations from baseline to week 12 · adult men and women who had been drinking from a household well with water arsenic concentrations greater than 50 μg/L for at least 1 year
1 finding from 1 review
Urinary arsenic Measured by percentage (%) of InAs, MMA, and DMA from baseline to week 12 · adult men and women who had been drinking from a household well with water arsenic concentrations greater than 50 μg/L for at least 1 year
1 finding from 1 review
Plasma homocysteine Measured by change in GM of plasma homocysteine concentrations from baseline to week 12 · adult men and women who had been drinking from a household well with water arsenic concentrations greater than 50 μg/L for at least 1 year
1 finding from 1 review
All‐cause mortality · adult men and women who had been exposed to arsenic‐containing drinking water
1 finding from 1 review
Neurocognitive function · adult men and women who had been exposed to arsenic‐containing drinking water
1 finding from 1 review
Any congenital anomalies · adult men and women who had been exposed to arsenic‐containing drinking water
1 finding from 1 review
Blood arsenic Measured by change in total blood arsenic, InAs, MMA, and DMA from baseline to week 12 · adult men and women who had been exposed to arsenic‐containing drinking water
1 finding from 1 review
Urinary arsenic Measured by change in percentage (%) of InAs, MMA, and DMA from baseline to week 12 · adult men and women who had been exposed to arsenic‐containing drinking water
1 finding from 1 review
Plasma homocysteine Measured by change in GM of plasma homocysteine concentrations from baseline to week 12 · adult men and women who had been exposed to arsenic‐containing drinking water
1 finding from 1 review
Any type of cancer · adult men and women who had been drinking from a household well with water arsenic concentrations greater than 50 μg/L for at least 1 year
1 finding from 1 review
All‐cause mortality · adult men and women who had been drinking from a household well with water arsenic concentrations greater than 50 μg/L for at least 1 year
1 finding from 1 review
BMD: % change in BMD at the lumbar spine · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Change in volumetric BMD of distal radius or tibia · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Change in fracture frequency · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Number of participants reporting an adverse event · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Change in NTX (assessed 4 to 6 months post‐intervention) · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Change in BAP (assessed 4 to 6 months post‐intervention) · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
ADHD symptoms · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
1 finding from 1 review
Clinical impression: severity ‐ not reported · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical impression: improvement‐ not reported · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found